Lipocine (NASDAQ:LPCN) Raised to “Hold” at Wall Street Zen

Lipocine (NASDAQ:LPCN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Weiss Ratings cut shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $15.00.

Lipocine Price Performance

Shares of NASDAQ LPCN opened at $2.23 on Friday. The business’s 50 day moving average price is $2.31 and its two-hundred day moving average price is $5.32. The company has a market cap of $18.38 million, a PE ratio of -1.19 and a beta of 0.44. Lipocine has a twelve month low of $1.81 and a twelve month high of $12.37.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.16 million. As a group, research analysts anticipate that Lipocine will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

A number of hedge funds have recently added to or reduced their stakes in LPCN. Citadel Advisors LLC acquired a new stake in shares of Lipocine during the 3rd quarter worth $41,000. Jane Street Group LLC acquired a new position in Lipocine in the fourth quarter valued at about $85,000. Dimensional Fund Advisors LP raised its stake in Lipocine by 57.5% in the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after purchasing an additional 6,982 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Lipocine during the first quarter worth about $185,000. Finally, Renaissance Technologies LLC grew its stake in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares in the last quarter. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.